HOME >> BIOLOGY >> NEWS
Wellcome Trust and GlaxoSmithKline announce partnership to target drug-resistant hospital infections

The Wellcome Trust and GlaxoSmithKline (GSK) today announced a collaboration to develop a new class of antibacterials to combat the rise of certain drug-resistant hospital-acquired infections, including those that lead to pneumonia. The collaboration is part of the Wellcome Trusts Seeding Drug Discovery initiative, aimed at tackling unmet medical needs.

GSK has received a 4 million award from the Trust to accelerate development of compounds for the treatment of Gram-negative bacteria which are becoming increasingly resistant to multiple antibacterials. GSK will make a matching contribution in staff, equipment, and other programme costs. The Trust will receive a financial consideration on any commercial product resulting from the collaboration.

"Our ability to tackle drug-resistant infections is reaching crisis level with few new antimicrobial agents on the horizon," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "Antibacterials are expensive to develop and may be held in reserve, limiting their market potential. It can be difficult, therefore, for companies to recoup their outlay in R&D costs.

This is where the Wellcome Trust believes it can make a difference through partnership. GSK has demonstrated a continuing commitment to discover and develop new antibacterials, aimed at addressing the growing threat of resistance. Our partnership will further support its research programmes."

The research will target Gram-negative bacteria, such as Pseudomonas, Klebsiella and Acinetobacter, which are increasingly resistant to available antibacterials and commonly cause hospital-acquired pneumonia and septic shock, particularly in patients in intensive care units. Without adequate therapy, patients often confront a poor prognosis mortality is high, and recovery, when it occurs, can be long and complicated.

Dr Patrick Vallance, Senior Vice President of Drug Discovery at GSK, commented: Infectio
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
29-Apr-2007


Page: 1 2

Related biology news :

1. Burroughs Wellcome Fund awards $14M to support physician-scientists
2. Burroughs Wellcome fund awards $8.25 million in grants to physician-scientists
3. Major Wellcome Trust award to take science from the bench to the bedside
4. A Wellcome brain gain for world leading neuroscience lab
5. Burroughs Wellcome Fund to support Project Suc-SEED at CIIT Centers for Health Research
6. BioMed Central applauds Wellcomes leadership on Open Access
7. Yale scientist studying virus infections named Burroughs Wellcome Investigator
8. Wilson Center and Pew Charitable Trusts expand efforts to examine risks/benefits of nanotechnology
9. Trusting your instincts leads you to the right answer
10. Leeds Teaching Hospitals NHS Trust to host press conference call/webcast on data published in NEJM
11. GlaxoSmithKlines rotavirus vaccine candidate shown effective

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/6/2019)... ... August 06, 2019 , ... A ... system that could have far-reaching implications for personalized medicine, especially when seeking treatments ... is able to predict which stem cell donors and manipulation methods might yield ...
(Date:8/4/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading experts ... so be sure to register today to save your place! Participate in the discussion ... upcoming webinars: , CLINICAL OPERATIONS , August 27 – Friend or Foe? An Assessment ...
(Date:8/1/2019)... ... 31, 2019 , ... Molecular Devices, LLC, a leader in ... of its FLIPR® Penta High-Throughput Cellular Screening System. , The new FLIPR Penta ... G-protein-coupled receptors (GPCRs) and ion channels, offering a new high-speed camera option capable ...
Breaking Biology News(10 mins):
(Date:6/12/2019)... TOWNSHIP, N.J. (PRWEB) , ... June 12, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... with Shanghai Zillion has been signed. The agreement will grant exclusive rights for ...
(Date:6/11/2019)... ... June 10, 2019 , ... DeepDyve and ... scientific journals to DeepDyve’s rental service for peer-reviewed journals. , IOPP’s portfolio ... more than 20 million articles, sourced from more than 15,000 journals. , “By ...
(Date:6/11/2019)... ... June 11, 2019 , ... A study released today in ... are able to incorporate into human CD34+ cells, modifying their gene expression and ... increased the cells’ ability to lodge into bone marrow. This research performed by ...
(Date:5/31/2019)... (PRWEB) , ... May 29, ... ... our patent applications from the USPTO providing proprietary interest to our methodology, ... FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our ...
Breaking Biology Technology:
Cached News: